ClinicalTrials.Veeva

Menu
C

Central Miami Medical Institute | Miami, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Azetukalner
Simufilam
Troriluzole
Semaglutide
Psilocybin
Semagludtide
KarXT
ACP-204
AVP-786
SEP-4199

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 18 total trials

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in ba...

Enrolling
Treatment Resistant Depression
Device: Vagus Nerve Stimulation (VNS)

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult part...

Enrolling
Bipolar II Disorder
Bipolar I Disorder
Drug: Placebo
Drug: Azetukalner

The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It wil...

Enrolling
Major Depressive Episode (MDE)
Depression
Drug: Placebo sublingual tablet
Drug: TNX-102 SL

This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...

Enrolling
Alzheimer's Disease Psychosis
Drug: Placebo
Drug: ACP-204

X-CEED-OLE is a Phase 3, multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner in adult participa...

Invitation-only
Bipolar II Disorder
Bipolar I Disorder
Drug: Azetukalner

The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administer...

Enrolling
NPS
Alzheimer Disease
Drug: IGC-AD1-Placebo
Drug: IGC-AD1-Active

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Active, not recruiting
Treatment Resistant Depression
Drug: Psilocybin
Status recently updated

This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatmen...

Enrolling
Active, not recruiting
Agitation
Alzheimer's Type Dementia
Drug: Masupirdine 100 mg
Drug: Placebo

Trial sponsors

Biohaven logo
C
Novo Nordisk logo
Otsuka logo
X
Acadia Pharmaceuticals logo
C
Karuna Therapeutics logo
LivaNova logo
Sumitomo Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems